Volume 8 Issue 3, Mar 2023

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)
Volume 8 Issue 3, Mar 2023:
Letter
Phase I study of camrelizumab in patients with advanced solid tumors
Yuxiang Ma,Jiaxin Cao  ORCID: orcid.org/0000-0002-8020-3603,Yang Zhang,Qianwen Liu,Wenfeng Fang,Yunpeng Yang,Yuanyuan Zhao,Qing Yang,Hongyun Zhao &…Li Zhang